Gopal S, Lu Q, Man JJ, et al. A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML. Blood Adv. 2018;2(14):1680-1684. doi:10.1182/bloodadvances.2018020396
Lee SCW, North K, Kim E, et al. Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell. 2018;34(2):225-241.e8. doi:10.1016/j.ccell.2018.07.003
Mertins P, Tang LC, Krug K, et al. Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry. Nat Protoc. 2018;13(7):1632-1661. doi:10.1038/s41596-018-0006-9
Rohban MH, Singh S, Wu X, et al. Systematic morphological profiling of human gene and allele function via Cell Painting. Elife. 2017;6. doi:10.7554/eLife.24060
Robertson G, Shih J, Yau C, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell. 2017;32(2):204-220.e15. doi:10.1016/j.ccell.2017.07.003
Mertins P, Udeshi ND, Clauser KR, et al. iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics. 2012;11(6):M111.014423. doi:10.1074/mcp.M111.014423
Sancak Y, Thoreen CC, Peterson TR, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007;25(6):903-15. doi:10.1016/j.molcel.2007.03.003
Rosenbluh J, Nijhawan D, Cox AG, et al. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151(7):1457-73. doi:10.1016/j.cell.2012.11.026
Lee MN, Roy M, Ong SE, et al. Identification of regulators of the innate immune response to cytosolic DNA and retroviral infection by an integrative approach. Nat Immunol. 2013;14(2):179-85. doi:10.1038/ni.2509
Conway KL, Goel G, Sokol H, et al. p40phox expression regulates neutrophil recruitment and function during the resolution phase of intestinal inflammation. J Immunol. 2012;189(7):3631-40. doi:10.4049/jimmunol.1103746